Company intelligence / Profile preview
Aquinnah Pharmaceuticals
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
Overview
Aquinnah has demonstrated preclinical efficacy for its lead oral small molecule targeting tau-stress granule interactions in advanced animal models of Alzheimer’s disease, showing ~70% reduction in pathological tau. The compound is designed as a once-daily pill with potential to combine with anti-amyloid drugs. ALS programs target TDP-43 pathology using similar approaches. No clinical trial results yet; most programs are preclinical or IND-enabling.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Aquinnah Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aquinnah Pharmaceuticals.